PUBLIC COMPANY
save$CADLCandel Therapeutics, Inc.
$CADLNeedham, MA, USupdated 13d ago
community read0 votes
pipeline
2
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Phase 11Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
- phase2CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC
- phase3Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer
- phase2Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)
- phase1Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer
- phase1GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas
- phase2Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma
- phase2Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma
Insider activity
source: SEC Form 4open-market buys + sells
- Feb 23, 26BUYManning Paul B· director$3.00M↗
routine RSU / option mechanics (3)
- Mar 31, 26grantManning Paul B · director4,618 sh
- Mar 31, 26grantPAPA JOSEPH C · director2,795 sh
- Mar 31, 26grantLoggia Nicoletta · director779 sh
🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
last refreshed 8m ago
Found something off?
comments(0)
5-min edit window · permanent after that